

The Florida Senate
BILL ANALYSIS AND FISCAL IMPACT STATEMENT

(This document is based on the provisions contained in the legislation as of the latest date listed below.)

Prepared By: The Professional Staff of the Committee on Judiciary

BILL: CS/CS/SB 1346

INTRODUCER: Judiciary Committee; Health Policy Committee; and Senators Polsky and Pizzo

SUBJECT: Fentanyl Testing

DATE: April 2, 2025

REVISED: _____

ANALYST	STAFF DIRECTOR	REFERENCE	ACTION
1. Looke	Brown	HP	Fav/CS
2. Davis	Cibula	JU	Fav/CS
3. _____	_____	RC	_____

Please see Section IX. for Additional Information:

COMMITTEE SUBSTITUTE - Technical Changes

I. Summary:

CS/CS/SB 1346 creates s. 395.1042, F.S., entitled “Gage’s Law.”¹ The bill requires a hospital or hospital-based off-campus emergency department to test a patient for fentanyl if the patient is receiving emergency services and care² for a possible drug overdose or poisoning and the hospital or stand-alone emergency department conducts a urine test to assist in diagnosing the individual. The bill specifies that if the urine test comes back positive for fentanyl, the hospital must perform a confirmation test as defined in s. 440.102(1), F.S.,³ and retain the results of the urine test and the confirmation test as part of the patient’s clinical record.

The bill provides an effective date of July 1, 2025.

¹ Gage’s Law is named after Gage Austin Taylor, an Orlando resident who died at 29 from an accidental fentanyl overdose on September 26, 2022. See [Tina Scott Polsky, Rita Harris file ‘Gage’s Law’ to mandate fentanyl tests in suspected overdose cases](#), (last visited March 27, 2025).

² Section 395.002(9), F.S., defines “emergency services and care” to mean medical screening, examination, and evaluation by a physician, or, to the extent permitted by applicable law, by other appropriate personnel under the supervision of a physician, to determine if an emergency medical condition exists and, if it does, the care, treatment, or surgery by a physician necessary to relieve or eliminate the emergency medical condition, within the service capability of the facility.

³ Section 440.102, F.S., defines a “confirmation test” to mean a second analytical procedure used to identify the presence of a specific drug or metabolite in a specimen, which test must be different in scientific principle from that of the initial test procedure and must be capable of providing requisite specificity, sensitivity, and quantitative accuracy.

II. Present Situation:

Fentanyl

According to the U.S. Drug Enforcement Administration, fentanyl is a synthetic opioid often used to treat patients who have chronic severe pain or experience severe pain after surgery. Fentanyl is a Schedule II controlled substance. It is similar to morphine but approximately 100 times more potent. When prescribed under the supervision of a licensed medical professional, fentanyl has a legitimate medical use to relieve pain. However, even patients who are prescribed fentanyl should be monitored for potential misuse or abuse of the drug.⁴

Illicit fentanyl is primarily manufactured in foreign, clandestine labs and smuggled into the country through Mexico. It is then distributed throughout the nation and sold on the illegal drug market. In order to increase its potency, fentanyl is mixed with other illicit drugs. It may be sold as powders and nasal sprays, but it is often pressed into pills that resemble legitimate prescription opioids. These counterfeit pills, which have no official oversight, often contain lethal doses of fentanyl.⁵

The risk is substantial that illegal drugs are intentionally contaminated with fentanyl. Because fentanyl is highly potent and relatively inexpensive, drug dealers mix fentanyl with other drugs including heroin, methamphetamine, and cocaine, which increases the likelihood of a fatal interaction.⁶

According to the Center for Disease Control, synthetic opioids like fentanyl are the primary cause of overdose deaths in the U.S.⁷

Urine Testing

Illicit drugs that are abused present a common area of interest for screening and urine testing. These five drugs are commonly tested in the United States using a urine screening:

- Cocaine.
- Amphetamines.
- Marijuana.
- Phencyclidine (PCP).
- Opioids.⁸

“Many assays include benzodiazepines as well. In addition to issues with false positives or negatives of the test, the standard urine assay will not screen for some existing illicit drugs. The epidemiology of drug use has shifted over the past 10 years, and there is a higher prevalence of substances such as synthetic cannabinoid, MDMA (ecstasy), and chemical variants of opioids and PCP, which may not be detected by many urine screenings. Other drugs of misuse that are

⁴ Facts About Fentanyl, United States Drug Enforcement Administration, available at <https://www.dea.gov/resources/facts-about-fentanyl> (last visited March 27, 2025).

⁵ *Id.*

⁶ *Id.*

⁷ *Id.*

⁸

generally unscreened include ketamine, chloral hydrate, gamma-hydroxybutyrate (GHB), psilocybin, and “bath salts” (cathinones).”⁹

The majority of urine drug screenings do not provide for quantitative testing, therefore, a simple “positive” or “negative” test “result is given if the assay detects substrate.”¹⁰

Serum Testing

Serum tests are used to screen for common, over-the-counter drugs which are often used for intentional overdoses. These serum “tests commonly obtain acetaminophen, aspirin, salicylates, and ethanol. Some extended serum screens include tricyclic antidepressants or barbiturates. Unlike urine screens, these tests are often quantitative and are useful in measuring blood concentrations. Concentrations require interpretation as to the reported times and amounts of ingestion, and often serial concentrations are necessary when the history is lacking or unreliable. While ethanol is detectable in the alcohol screen, other toxic alcohols like methanol, ethylene glycol, and isopropyl alcohol are not detectable.”¹¹

III. Effect of Proposed Changes:

The bill creates s. 395.1042, F.S., entitled “Gage’s Law.” The bill requires that any hospital or stand-alone emergency department include fentanyl when testing a patient’s urine to assist in diagnosing a suspected overdose or poisoning and while providing emergency services and care.

If the results are positive for fentanyl, the hospital is required to perform a confirmation test as defined in s. 440.102(1), F.S. The bill specifies that the results of the urine test as well as the confirmation test must be preserved in the patient’s clinical record for the timeframe required by the hospital’s or stand-alone emergency department’s clinical recordkeeping practices.

The bill provides an effective date of July 1, 2025.

IV. Constitutional Issues:

A. Municipality/County Mandates Restrictions:

None.

B. Public Records/Open Meetings Issues:

None.

C. Trust Funds Restrictions:

None.

⁹ *Id.*

¹⁰ *Id.*

¹¹ *Id.*

D. State Tax or Fee Increases:

None.

E. Other Constitutional Issues:

None.

V. Fiscal Impact Statement:

A. Tax/Fee Issues:

None.

B. Private Sector Impact:

The bill may require individuals or health insurers to incur additional costs for testing a patient for fentanyl.

C. Government Sector Impact:

The bill may require government run hospitals and insurers to incur additional costs for testing a patient for fentanyl.

VI. Technical Deficiencies:

None.

VII. Related Issues:

The bill requires a hospital to conduct a confirmation test for fentanyl under certain circumstances but does not provide a hospital with an exception if the patient refuses the confirmation test and does not provide a timeframe for the test to be conducted. As such, it may be advisable to clarify in the bill under what time frame the confirmation test must be performed as well as the hospital's responsibility should a patient refuse the test.

It may also be advisable to provide the Agency for Health Care Administration (AHCA) with specific rulemaking authority to implement the new section of law in order to give AHCA flexibility to address issues with implementation of the new requirement.

VIII. Statutes Affected:

This bill creates section 395.1042 of the Florida Statutes.

IX. Additional Information:

A. Committee Substitute – Statement of Changes:

(Summarizing differences between the Committee Substitute and the prior version of the bill.)

CS/CS by Judiciary on April 1, 2025:

The committee substitute makes a technical change for consistency by clarifying that the “confirmation test” required in s. 395.1042(2)(b), F.S., is also a “confirmation test” in s. 395.1042(2)(c), F.S., and not “laboratory and toxicology screenings” as appeared in the prior version of the bill.

CS by Health Policy on March 25, 2025:

The committee substitute removes the requirement for a hospital to perform “laboratory and toxicology screenings” should a patient’s urine test positive for fentanyl and replaces it with the requirement to conduct a “confirmation test” as defined in s. 440.102(1), F.S.

B. Amendments:

None.